Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177139 | 0.83 | DRD3 (0.44) | DRD3CASP3ALDH1A1MEN1GAA | |
| SCHEMBL28669956 | 0.79 | DRD3 (0.41) | DRD3CASP3ALDH1A1TSHRMAPK1 | |
| SCHEMBL6050329 | 0.79 | NR1H2 (0.46) | DRD3ALDH1A1CA12CA9TDP1 | |
| SCHEMBL5190685 | 0.78 | ALDH1A1 (0.44) | CASP3ALDH1A1GAACA12CA9 | |
| SCHEMBL27338871 | 0.78 | CA12 (0.44) | CASP3ALDH1A1MAPK1GAARAB9A | |
| SCHEMBL2183011 | 0.78 | CASP3 (0.40) | CASP3ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL8328628 | 0.77 | NR1H2 (0.49) | ALDH1A1CA12CA9 | |
| SCHEMBL8332447 | 0.77 | NR1H2 (0.49) | ALDH1A1CA12CA9 | |
| SCHEMBL6214680 | 0.77 | DRD3 (0.40) | DRD3CASP3ALDH1A1MEN1GAA | |
| SCHEMBL8331683 | 0.77 | NR1H2 (0.49) | ALDH1A1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | claimed |
| EP-0876428-B1 | SULFO BENZ e]INDOCYANINE FLUORESCENT DYES | INNOSENSE S R L (IT) | 2004-11-17 | — | — | EP | claimed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | claimed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2003-03-13 | — | — | US | claimed |
| EP-0865339-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2003-01-22 | — | — | EP | claimed |
| US-6479502-B1 | TREATMENT OF DISEASES AND CONDITIONS RESPONSIVE TO MODULATION OF MATRIX METALLOPROTEINASE ACTIVITY | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2002-11-12 | — | — | US | claimed |
| EP-1107953-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-06-20 | — | — | EP | claimed |
| US-6136612-A | THAT CAN BE EXCITED USING INEXPENSIVE LIGHT EMITTING DIODES AND DIODE LASERS, EXHIBIT GOOD WATER SOLUBILITY, AND CAN BE CONJUGATED TO A WIDE VARIETY OF MOLECULES OR SURFACES FOR LABELING PURPOSES; USE IN IMMUNOASSAY, DNA PROBES | SORIN BIOMEDICA CARDIO S.P.A. (IT) | 2000-10-24 | — | — | US | claimed |
| US-6103739-A | BONE RESORPTION; ANTIINFLAMMATORY AGENTS, SKIN DISORDERS; ANTITUMOR-CARCINOGENIC AND METASTASES AGENTS; ANGIOGENESIS INHIBITORS; ANTIARRITHIC AGENTS; RHEUMATOID DISEASES; OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS AND CORNEAL ULCERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-08-15 | — | — | US | claimed |
| WO-2000012477-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| EP-0944597-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | claimed |
| EP-0876428-A1 | SULFO BENZ e]INDOCYANINE FLUORESCENT DYES | SORIN BIOMEDICA CARDIO S.p.A. (IT) | 1998-11-11 | — | — | EP | claimed |
| EP-0865339-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-09-23 | — | — | EP | claimed |
| WO-1998023588-A9 | METALLOPROTEINASE INHIBITORS | — | 1998-09-17 | — | — | WO | claimed |
| WO-1998023588-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-04 | — | — | WO | claimed |
| WO-1997013810-A1 | SULFO BENZ[e]INDOCYANINE FLUORESCENT DYES | SORIN BIOMEDICA CARDIO S.P.A. (IT) | 1997-04-17 | — | — | WO | claimed |
| WO-1997003783-A9 | METALLOPROTEINASE INHIBITORS | — | 1997-04-03 | — | — | WO | claimed |
| WO-1997003783-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| CN-1976915-A | HIV integrase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-06-06 | — | — | CN | disclosed |
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-6916800-B2 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | PFIZER INC (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | disclosed |
| WO-2003057688-A2 | OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-07-17 | — | — | WO | disclosed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2003-03-13 | — | — | US | disclosed |
| EP-0865339-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2003-01-22 | — | — | EP | disclosed |
| US-6479502-B1 | TREATMENT OF DISEASES AND CONDITIONS RESPONSIVE TO MODULATION OF MATRIX METALLOPROTEINASE ACTIVITY | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2002-11-12 | — | — | US | disclosed |
| US-6288061-B1 | INTERLEUKIN INHIBITORS; ASTHMA, BRONCHODILATOR AGENTS, ANTIALLERGENS | WELFIDE CORPORATION (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-1107953-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-06-20 | — | — | EP | disclosed |
| US-6103739-A | BONE RESORPTION; ANTIINFLAMMATORY AGENTS, SKIN DISORDERS; ANTITUMOR-CARCINOGENIC AND METASTASES AGENTS; ANGIOGENESIS INHIBITORS; ANTIARRITHIC AGENTS; RHEUMATOID DISEASES; OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS AND CORNEAL ULCERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-08-15 | — | — | US | disclosed |
| WO-2000012477-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| EP-0944597-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | disclosed |
| EP-0766688-A4 | SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0865339-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1998023588-A9 | METALLOPROTEINASE INHIBITORS | — | 1998-09-17 | — | — | WO | disclosed |
| WO-1998023588-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-04 | — | — | WO | disclosed |
| EP-0766688-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| WO-1997003783-A9 | METALLOPROTEINASE INHIBITORS | — | 1997-04-03 | — | — | WO | disclosed |
| WO-1997003783-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |
| WO-1995032980-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| EP-0600831-A1 | Phtalazinon derivatives | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0600830-A1 | Substituted derivatives of diaminophthalimide as protein-tyrosine kinase inhibitors | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0600832-A1 | Derivatives of diamino benzoic and diamino phthalic acid und their use as protein linase inhibitors | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0111281-B1 | NEW CEPHEM COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-06-06 | — | — | EP | disclosed |
| US-4839365-A | Thienopyridine derivatives useful in treating gastric ulcers | SHINOGI & CO., LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0292051-A2 | Thienopyridine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-11-23 | — | — | EP | disclosed |
| US-4719206-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-01-12 | — | — | US | disclosed |
| US-4584290-A | MICROBIOCIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-22 | — | — | US | disclosed |
| EP-0111281-A2 | New cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-20 | — | — | EP | disclosed |
| US-4439433-A | CEPHALOSPORIN ANTIBIOTICS | ROUSSEL UCLAF (FR) | 1984-03-27 | — | — | US | disclosed |
| US-4138551-A | DINUCLEAR CYANINE OR MEROCYANINE DYE REACTIVE WITH HYDROPHILIC COLLODI | CIBA-GEIGY AG (CH) | 1979-02-06 | — | — | US | disclosed |
| US-4138551-A | DINUCLEAR CYANINE OR MEROCYANINE DYE REACTIVE WITH HYDROPHILIC COLLODI | CIBA-GEIGY AG (CH) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | CHRM3, CYSLTR2, CHRM2 | DRD3 1552/4885CASP3 3391/4885ALDH1A1 1220/4885 |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | HRH4, HRH2, HTR4 | DRD3 342/4885CASP3 4026/4885ALDH1A1 2035/4885 |
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | MMP2, CTSH, TIMP3 | DRD3 4718/4885CASP3 408/4885ALDH1A1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.